scholarly journals Production of a TEM-24 Plasmid-Mediated Extended-Spectrum β-Lactamase by a Clinical Isolate ofPseudomonas aeruginosa

2000 ◽  
Vol 44 (1) ◽  
pp. 213-216 ◽  
Author(s):  
Helene Marchandin ◽  
Helene Jean-Pierre ◽  
Christophe De Champs ◽  
Danielle Sirot ◽  
Helene Darbas ◽  
...  
Keyword(s):  
Escherichia Coli ◽  
Pseudomonas Aeruginosa ◽  
Clinical Isolate ◽  
Proteus Mirabilis ◽  
Enterobacter Aerogenes ◽  
E Coli ◽  
Extended Spectrum ◽  
Resistance Markers

ABSTRACT Several Pseudomonas aeruginosa strains, including one urinary isolate producing an extended-spectrum β-lactamase TEM-24, were isolated from a long-term-hospitalized woman. Three TEM-24-producing enterobacterial species (Enterobacter aerogenes, Escherichia coli, and Proteus mirabilis) were isolated from the same patient. TEM-24 and the resistance markers for aminoglycosides, chloramphenicol, and sulfonamide were encoded by a 180-kb plasmid transferred by conjugation into E. coli HB101.

Community spread of extended-spectrum β-lactamase-producing Escherichia coli, Klebsiella pneumoniae and Proteus mirabilis: a long-term study in Japan

2013 ◽  
Vol 62 (7) ◽  
pp. 1038-1043 ◽  
Author(s):  
Yong Chong ◽  
Shinji Shimoda ◽  
Hiroko Yakushiji ◽  
Yoshikiyo Ito ◽  
Toshihiro Miyamoto ◽  
...  
Keyword(s):  
Escherichia Coli ◽  
Klebsiella Pneumoniae ◽  
Proteus Mirabilis ◽  
Epidemiological Data ◽  
Detection Rates ◽  
E Coli ◽  
Long Term Study ◽  
Extended Spectrum ◽  
Few Data

Community-acquired infections caused by extended-spectrum β-lactamase (ESBL)-producing bacteria, particularly CTX-M-producing Escherichia coli, are a rising concern worldwide. There are few data from Japan on the acquisition of ESBLs in the community or the influx of these bacteria into hospitals. Therefore, we examined the prevalence of ESBL carriage in outpatients, in order to estimate the spread of ESBLs in community settings. We analysed bacterial isolates from outpatient samples at our institution over a 9-year period from 2003 to 2011, with respect to epidemiological data on ESBL-producing bacteria and their genotypic features. Out of 5137 isolates, 321 (6.3 %) were ESBL producers, including E. coli, Klebsiella pneumoniae and Proteus mirabilis. The detection rates of the ESBL-producing isolates gradually increased and reached 14.3, 8.7 and 19.6 % for E. coli, K. pneumoniae and P. mirabilis strains, respectively, in 2011. Genotyping analysis showed that many of the strains produced multiple β-lactamases, including TEM, SHV and CTX-M, rather than just CTX-M. The CTX-M-9 group was dominant among the CTX-M genotypes; further, the CTX-M-1 and M-2 groups were also detected (~30 %). This is believed to be the first report from Japan showing a definite increase in ESBL detection in outpatients. In addition, our findings suggest the simultaneous community spread of diverse ESBL genotypes, not an expansion of particular ESBL genes.

Антимікробна резистентність провідних збудників інфекцій сечових шляхів у Києві (Україна)

2017 ◽  
Vol 1 (2) ◽  
pp. 48-60
Author(s):  
A.G. Salmanov ◽  
A.V. Rudenko
Keyword(s):  
Escherichia Coli ◽  
Pseudomonas Aeruginosa ◽  
Klebsiella Pneumoniae ◽  
Staphylococcus Epidermidis ◽  
Klebsiella Oxytoca ◽  
Enterobacter Aerogenes ◽  
Enterobacter Cloacae ◽  
Proteus Vulgaris ◽  
Providencia Rettgeri ◽  
E Coli

Мета роботи — вивчити резистентність до антибіотиків бактеріальних збудників інфекцій сечових шляхів (ІСШ), виділених у пацієнтів урологічного стаціонару в м. Києві. Матеріали і методи. Досліджено 1612 штамів бактерій, виділених із сечі хворих з ІСШ (цистит, уретрит, пієлонефрит), госпіталізованих в урологічне відділення ДУ «Інститут урології НАМН України» у м. Києві протягом 2016 р. Серед пацієнтів переважали жінки — 1201 (74,5 %). Вік хворих становив від 17 до 74 років. Для збору даних використано медичну документацію лікарні. Мікробіологічні дослідження виконано у лабораторії мікробіології ДУ «Інститут урології НАМН України». Аналізували результати культурального дослідження зразків сечі, зібраних за наявності клінічних ознак ІСШ. Дослідження клінічного матеріалу та інтерпретацію отриманих результатів проводили загальноприйнятими методами. Вивчено чутливість уропатогенів до 31 антибіотика дискодифузійним методом відповідно до рекомендацій Інституту клінічних та лабораторних стандартів США (Clinical and Laboratory Standards Institute (CLSI)). Результати та обговорення. Аналіз мікробного спектра сечі виявив домінування серед уропатогенів штамів Escherichia coli (32,0 %), Enterococcus faecalis (19,5 %), Klebsiella pneumoniae (10,9 %), Staphylococcus epidermidis (8,9 %), S. haemolyticus (6,5 %) та Pseudomonas aeruginosa (6,4 %). Частка Enterococcus faecium, Enterobacter aerogenes і Streptococcus viridans становила відповідно 2,5, 2,2 і 1,6 %, Enterobacter cloacae, Klebsiella oxytoca, Acinetobacter baumannii, Proteus vulgaris та Providencia rettgeri — менше 1,0 %. У більшості випадків (69,7 %) мікроорганізми виділено у монокультурі, у решті випадків — у мікробних асоціа- ціях. Високу резистентність до тестованих антибіотиків виявили штами E. aerogenes (45,1 %), E. cloacae (45,7 %), E. faecium (40,9 %), E. faecalis (40,7 %), E. coli (39,9 %), P. aeruginosa (34,0 %), K. pneumoniae (28,6 %). Найбільш активними до уропатогенів були іміпенем (E. coli — 87,6 %, P. aeruginosa — 75,7 %, E. cloacae — 67,3 %, E. aerogenes — 72,6 %, K. pneumoniae — 93,2 %), меропенем (E. coli — 89,1 %, P. aeruginosa — 76,7 %, K. pneumoniae — 82,6 %), лефлоцин (E. coli — 74,5 %, ентерококи — 78,7 %, P. aeruginosa — 76,7 %, E. cloacae — 73,9 %, E. aerogenes — 80,4 %, K. pneumoniae — 83,5 %), амоксицилін/клавуланат (ентерококи — 84,6 %), фурагін (ентерококи — 82,6 %), цефоперазон (K. pneumoniae — 89,2 %, P. aeruginosa — 73,8 %), цефтріаксон (K. pneumoniae — 80,1 %). Висновки. Антибіотикорезистентність збудників ІСШ — важлива терапевтична проблема. Найбільшою активністю до уропатогенів характеризуються іміпенем, меропенем, лефлоцин, амоксицилін/ клавуланат, фурагін, цефоперазон, цефтріаксон, які можна розглядати як препарат вибору для призначення стартової терапії ІСШ. Необхідно здійснювати постійний моніторинг за резистентністю до дії антибіотиків. Політику використання антибіотиків у кожному стаціонарі слід визначати залежно від локальних даних щодо резистентності до протимікробних препаратів.

scholarly journals Nationwide Study of the Prevalence, Characteristics, and Molecular Epidemiology of Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae in France

2007 ◽  
Vol 52 (2) ◽  
pp. 786-789 ◽  
Author(s):  
Muriel Galas ◽  
Jean-Winoc Decousser ◽  
Nelly Breton ◽  
Thierry Godard ◽  
Pierre Yves Allouch ◽  
...  
Keyword(s):  
Escherichia Coli ◽  
Klebsiella Pneumoniae ◽  
Molecular Epidemiology ◽  
Molecular Analysis ◽  
Enterobacter Aerogenes ◽  
Nationwide Study ◽  
E Coli ◽  
Extended Spectrum ◽  
Prevalent Species

ABSTRACT Among 10,872 isolates of Enterobacteriaceae from a nationwide study of 88 French hospitals in 2005, 169 (1.7%) expressed an extended-spectrum β-lactamase. The most prevalent species were Escherichia coli (48.5%), Enterobacter aerogenes (23.7%), and Klebsiella pneumoniae (14.8%). Molecular analysis underlined the polyclonal spread of CTX-M-expressing E. coli, primarily isolates of the CTX-M-1 subgroup.

scholarly journals Fatores de risco e perfil do uso de antimicrobianos entre pacientes com infecção no trato urinário em uma unidade de terapia intensiva

2021 ◽  
Vol 10 (3) ◽  
pp. e43910313516
Author(s):  
Lucas Harassim ◽  
Olibio Lopes Fiebig da Silva ◽  
Luiz Felipe Soares Pinheiro ◽  
Elber José Assaiante dos Santos ◽  
Cláudio Daniel Cerdeira ◽  
...  
Keyword(s):  
Escherichia Coli ◽  
Staphylococcus Aureus ◽  
Pseudomonas Aeruginosa ◽  
Klebsiella Oxytoca ◽  
Enterobacter Aerogenes ◽  
Enterobacter Cloacae ◽  
Citrobacter Freundii ◽  
Providencia Rettgeri ◽  
E Coli ◽  
Terapia Intensiva

A Infecção no Trato Urinário (ITU) acometendo pacientes em Unidades de Terapia Intensiva (UTIs) é uma realidade preocupante, agravada pelo uso irracional de antimicrobianos e a alarmante multirresistência em microrganismos. Nós avaliamos o nível de assertividade quanto ao uso de antimicrobianos durante à antibioticoterapia empírica (ATE), em pacientes diagnosticados com ITU, comparando tal tratamento farmacológico empírico e o realizado após o antibiograma (antibioticoterapia direcionada), além disto, estimamos a prevalência dos agentes etiológicos e analisamos os fatores de risco associados. Este é um estudo observacional e transversal, realizado em 2015, no qual foram avaliados pacientes de ambos os sexos e todas as idades apresentando ITU e submetidos à antibioticoterapia, internados em uma UTI de um hospital no sul de Minas Gerais, Brasil. Dos 49 pacientes avaliados (28 mulheres [M] e 21 homens [H]), a média de idade foi 55±19 anos (IC(95) 49-61) e a faixa etária ≥70 anos foi a predominante. Quatorze diferentes microrganismos foram causadores de ITUs, sendo que 28,3% (IC(95%) 16,2-40,4) dos isolados clínicos tiveram Escherichia coli como o agente etiológico (33,3% H e 28,6% M); 18,9% (IC(95%) 8,3-29,4) Acinetobacter baumannii (33,3% H e 10,7% M); 15,1% (IC(95%) 5,5-24,7) Klebsiella pneumoniae (19% H e 14,3% M); 11,3% Pseudomonas aeruginosa (9,5% H e 14,3% M); 5,7% Enterobacter aerogenes (14,3% H); 3,8% Klebsiella oxytoca; 3,8% Staphylococcus aureus (7,1% M); e 1,9% para cada um dos seguintes microrganismos: Enterococcus faecalis (4,8% H); Proteus mirabilis (3,6% M); Enterobacter cloacae (3,6% M); Providencia rettgeri (4,8% H); Citrobacter koseri (3,6% M); Citrobacter freundii (3,6% M); e Fungos leveduriformes (4,8% H). As prevalências de ITUs causadas por A. baumannii e P. aeruginosa foram influenciadas pelo sexo (χ² com p<0,001). No sexo masculino, houve correlações positivas “substanciais” entre o aumento da idade (em anos) e a prevalência de ITU causada por E. coli (r = 0,69) ou entre idades menos avançadas e a prevalência de ITU causada por A. baumannii (r = -0,7). No sexo feminino, houve uma correlação positiva “extremamente forte” entre o aumento da idade e a prevalência de ITU causada por E. coli (r = 0,94; IC(95) 0,66-0,99; p<0,0014). Os antibióticos mais utilizados de forma empírica (ATE) foram: Ciprofloxacina (14,3% IC(95%) 4,7-24,1), Cefepima (14,3%) e Vancomicina (10%), e após o antibiograma (antibioticoterapia direcionada): Ceftazidima (16,3% IC(95%) 6-26,7), Ciprofloxacina (14,3% IC(95%) 4,5-24,1), Polimixina B (10,2%), Imipenem (10,2%) e Ampicilina + Sulbac. (8,2%). Em 20% dos casos, as terapias empíricas (ATE) foram consideradas “inapropriadas/não acertadas”. Contudo, também devemos ter ciência da necessidade clínica e quanto ao imediatismo para o tratamento de uma ITU em UTI, uma vez que a doença pode ser fatal se uma terapia não for instituída, portanto, nós aconselhamos avaliações mais minuciosas, tanto da racionalidade do uso de antibióticos, quanto dos fatores de risco para o desenvolvimento de ITUs em UTIs.

scholarly journals Profil Penggunaan Antibiotik dan Peta Kuman pada Pasien Gangren Diabetes Melitus di Sebuah RSUD di Kabupaten Gresik

2020 ◽  
Vol 3 (2) ◽  
pp. 96
Author(s):  
Isna Romadhona ◽  
Fauna Herawati ◽  
Rika Yulia
Keyword(s):  
Escherichia Coli ◽  
Staphylococcus Aureus ◽  
Pseudomonas Aeruginosa ◽  
Klebsiella Pneumoniae ◽  
Acinetobacter Baumannii ◽  
Proteus Mirabilis ◽  
Enterobacter Aerogenes ◽  
Enterobacter Cloacae ◽  
Proteus Vulgaris ◽  
Diabetes Melitus

Antibiotik merupakan obat yang digunakan untuk mengatasi dan mencegah infeksi bakteri. Penggunaan antibiotik yang tidak tepat dapat menimbulkan berbagai masalah, diantaranya pengobatan akan lebih mahal dan juga risiko terjadinya resistensi bakteri terhadap antibiotik. Penelitian ini bertujuan untuk mengetahui profil penggunaan antibiotik dan profil peta kuman pada pasien gangren diabetes melitus di sebuah RSUD di Kabupaten Gresik serta untuk mengetahui kesesuaian penggunaan antibiotik dengan mengacu pada Permenkes Republik Indonesia No. 2406/Menkes/PER/XII/2011. Data penggunaan antibiotik diperoleh dari catatan Rekam Medis pada periode Januari – November 2017. Data penggunaan antibiotik dihitung dengan menggunakan rumus DDD/100 pasien-hari rawat. Hasil perhitungan DDD/100 pasien-hari rawat menunjukkan hasil sebesar 470,11 DDD/100 pasien-hari rawat. Peta kuman pada pasien gangren, melaporkan adanya bakteri Enterobacter cloacae 24%, Escherichia coli 18%, Staphylococcus aureus 15%, Acinetobacter baumannii 9%, Pseudomonas aeruginosa 6%, Citrobacter youngae 6%, Enterobacter aerogenes 6%, Proteus vulgaris 6%, Staphylococcus schleiferi 6%, Klebsiella pneumoniae 3%, dan Proteus mirabilis 3% . Penggunaan antibiotik seftriakson dan metronidazol pada pasien gangren diabetes melitus di sebuah RSUD di Kabupaten Gresik pada periode Januari – November 2017 telah sesuai dengan pedoman penggunaan antibiotik berdasarkan Permenkes Republik Indonesia No. 2406/Menkes/PER/ XII/2011, yaitu antibiotik golongan sefalosporin generasi III yang lebih aktif terhadap Enterobacteriaceae dan antibiotik golongan nitroimidazol yang dapat mengobati infeksi bakteri basil anerob Gram-Negatif.

Colonization resistance against potentially pathogenic bacteria in hexaflora-associated gnotobiotic mice

1978 ◽  
Vol 24 (2) ◽  
pp. 79-83 ◽  
Author(s):  
Kunwar K. Srivastava
Keyword(s):  
Escherichia Coli ◽  
Pseudomonas Aeruginosa ◽  
Pathogenic Bacteria ◽  
Enterobacter Aerogenes ◽  
Lactobacillus Brevis ◽  
Colonization Resistance ◽  
Post Challenge ◽  
E Coli ◽  
Gnotobiotic Mice ◽  
Akr Mice

A study of colonization resistance against potentially pathogenic bacteria (Escherichia coli and Pseudomonas aeruginosa) was conducted in hexaflora-associated gnotobiotic mice. Groups of germfree AKR mice were swabbed with five bacterial and a single gastrointestinal yeast species: Streptococcus faecalis, Lactobacillus brevis, Staphylococcus epidermidis, Enterobacter aerogenes, Bacteroides fragilis var. vulgatus, and Torulopsis sp. All species became established in the gut in 8 weeks. Later these associated mice were divided and challenged by four graded doses of E. coli or P. aeruginosa. The presence of challenge organism was monitored specifically in the freshly voided fecal specimens of the challenged mice. Escherichia coli colonized the gut of each mouse at each level up to 60 days post challenge. Pseudomonas aeruginosa was completely eliminated from each mouse at each dose level after 30 days post challenge. Evidence suggests that all six species were sufficient to prevent the colonization of P. aeruginosa and not of E. coli in the gut of the gnotobiotic mice.

scholarly journals The Occurrence of blaCTX-M, blaSHV, and blaTEM Genes in Extended-Spectrum β-Lactamase-Positive Strains of Klebsiella pneumoniae, Escherichia coli, and Proteus mirabilis in Poland

2014 ◽  
Vol 2014 ◽  
pp. 1-7 ◽  
Author(s):  
Dominika Ojdana ◽  
Paweł Sacha ◽  
Piotr Wieczorek ◽  
Sławomir Czaban ◽  
Anna Michalska ◽  
...  
Keyword(s):  
Escherichia Coli ◽  
Multidrug Resistance ◽  
Klebsiella Pneumoniae ◽  
Proteus Mirabilis ◽  
Bacterial Strains ◽  
E Coli ◽  
Extended Spectrum ◽  
Genes Encoding

Bacteria belonging to the Enterobacteriaceae family that produce extended-spectrum β-lactamase (ESBL) enzymes are important pathogens of infections. Increasing numbers of ESBL-producing bacterial strains exhibiting multidrug resistance have been observed. The aim of the study was to evaluate the prevalence of blaCTX-M, blaSHV, and blaTEM genes among ESBL-producing Klebsiella pneumoniae, Escherichia coli, and Proteus mirabilis strains and to examine susceptibility to antibiotics of tested strains. In our study, thirty-six of the tested strains exhibited blaCTX-M genes (blaCTX-M-15, blaCTX-M-3, blaCTX-M-91, and blaCTX-M-89). Moreover, twelve ESBL-positive strains harbored blaSHV genes (blaSHV-18, blaSHV-7, blaSHV-2, and blaSHV-5), and the presence of a blaTEM gene (blaTEM-1) in twenty-five ESBL-positive strains was revealed. Among K. pneumoniae the multiple ESBL genotype composed of blaCTX-M-15, blaCTX-M-3, blaSHV-18, blaSHV-7, blaSHV-2, and blaSHV-5 genes encoding particular ESBL variants was observed. Analysis of bacterial susceptibility to antibiotics revealed that, among β-lactam antibiotics, the most effective against E. coli strains was meropenem (100%), whereas K. pneumoniae were completely susceptible to ertapenem and meropenem (100%), and P. mirabilis strains were susceptible to ertapenem (91.7%). Moreover, among non-β-lactam antibiotics, gentamicin showed the highest activity to E. coli (91.7%) and ciprofloxacin the highest to K. pneumoniae (83.3%). P. mirabilis revealed the highest susceptibility to amikacin (66.7%).

scholarly journals AmpC β-Lactamase in an Escherichia coli Clinical Isolate Confers Resistance to Expanded-Spectrum Cephalosporins

2004 ◽  
Vol 48 (10) ◽  
pp. 4050-4053 ◽  
Author(s):  
Hedi Mammeri ◽  
Hasan Nazic ◽  
Thierry Naas ◽  
Laurent Poirel ◽  
Sophie Léotard ◽  
...  
Keyword(s):  
Escherichia Coli ◽  
Amino Acid ◽  
Clinical Isolate ◽  
Biochemical Analysis ◽  
Amino Acid Substitutions ◽  
E Coli ◽  
Extended Spectrum

ABSTRACT Cloning, sequencing, and biochemical analysis identified a novel AmpC-type β-lactamase conferring resistance to extended-spectrum cephalosporins in an Escherichia coli clinical isolate. This enzyme, exhibiting 14 amino acid substitutions compared to a reference AmpC cephalosporinase of E. coli, hydrolyzed ceftazidime and cefepime significantly.

scholarly journals Long-Term Persistence of blaCTX-M-15 in Soil and Lettuce after Introducing Extended-Spectrum β-Lactamase (ESBL)-Producing Escherichia coli via Manure or Water

2020 ◽  
Vol 8 (11) ◽  
pp. 1646
Author(s):  
Maria-Theresia Gekenidis ◽  
Serena Rigotti ◽  
Jörg Hummerjohann ◽  
Fiona Walsh ◽  
David Drissner
Keyword(s):  
Escherichia Coli ◽  
Food Group ◽  
Resistant Bacteria ◽  
Antibiotic Resistant ◽  
E Coli ◽  
Extended Spectrum ◽  
Infection Treatment ◽  
Human Food Chain

The number of environmental antibiotic-resistant bacteria (ARB) has increased dramatically since the start of antibiotic mass production for broad bacterial infection treatment in 1944. Nowadays, ARB and their resistance-determining genes (ARGs) are readily detected in all environments, including the human food chain. A highly relevant food group in this context is fresh produce, frequent raw consumption of which facilitates direct transfer of ARB and ARGs to the consumer. Here, we investigate the persistence of an extended-spectrum β-lactamase (ESBL)-producing Escherichia coli (E. coli) pEK499 and its clinically most important ARG (blaCTX-M-15), after introduction via irrigation water or manure into a lettuce-growing system. Culturable ESBL-producing E. coli persisted longest in soil and when introduced via manure (until 9 weeks after introduction), while being undetectable on lettuce beyond day 7. In contrast, qPCR detection of blaCTX-M-15 was much more frequent: introduction via water significantly increased blaCTX-M-15 on lettuce until week 4, as opposed to manure, which affected the soil in the long-term (9 weeks) while leading to blaCTX-M-15 detection on lettuce until day 7 only. Our findings demonstrate long-term persistence of undesired ARB and ARG after their introduction via both irrigation and amendment. Such an understanding of the persistence kinetics of an ESBL-producing E. coli and plasmid-encoded blaCTX-M-15 aids the determination of critical actions in order to mitigate their transfer to the consumer.

scholarly journals Characterization and Sequence Analysis of Extended-Spectrum-β-Lactamase-Encoding Genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis Isolates Collected during Tigecycline Phase 3 Clinical Trials

2008 ◽  
Vol 53 (2) ◽  
pp. 465-475 ◽  
Author(s):  
C. Hal Jones ◽  
Margareta Tuckman ◽  
David Keeney ◽  
Alexey Ruzin ◽  
Patricia A. Bradford
Keyword(s):  
Escherichia Coli ◽  
Clinical Trials ◽  
Klebsiella Pneumoniae ◽  
Proteus Mirabilis ◽  
Confirmatory Test ◽  
Phase 3 ◽  
E Coli ◽  
Current Trends ◽  
Extended Spectrum ◽  
Genes Encoding

ABSTRACT In concert with the development of novel β-lactams and broad-spectrum cephalosporins, bacterially encoded β-lactamases have evolved to accommodate the new agents. This study was designed to identify, at the sequence level, the genes responsible for the extended-spectrum-β-lactamase (ESBL) phenotypes of Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during the global tigecycline phase 3 clinical trials. PCR assays were developed to identify and clone the bla TEM, bla SHV, bla OXA, and bla CTX genes from clinical strains. Isolates were also screened for AmpC genes of the bla CMY, bla ACT, bla FOX, and bla DHA families as well as the bla KPC genes encoding class A carbapenemases. E. coli, K. pneumoniae, and P. mirabilis isolates with ceftazidime MICs of ≥2 μg/ml were designated possible ESBL-producing pathogens and were then subjected to a confirmatory test for ESBLs by use of Etest. Of 272 unique patient isolates, 239 were confirmed by PCR and sequencing to carry the genes for at least one ESBL, with 44% of the positive isolates harboring the genes for multiple ESBLs. In agreement with current trends for ESBL distribution, bla CTX-M-type β-lactamase genes were found in 83% and 71% of the ESBL-positive E. coli and K. pneumoniae isolates, respectively, whereas bla SHV genes were found in 41% and 28% of the ESBL-positive K. pneumoniae and E. coli isolates, respectively. Ninety-seven percent of the E. coli and K. pneumoniae isolates were tigecycline susceptible (MIC90 = 2 μg/ml), warranting further studies to define the therapeutic utility of tigecycline against strains producing ESBLs in a clinical setting.

Sign in / Sign up

Export Citation Format

Share Document